These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effects of flumazenil on ethanol withdrawal syndrome in rats.
    Author: Uzbay IT, Akarsu ES, Kayaalp SO.
    Journal: Arzneimittelforschung; 1995 Feb; 45(2):120-4. PubMed ID: 7710430.
    Abstract:
    Effects of flumazenil (Ro 15-1788, CAS 78755-81-4) on ethanol withdrawal syndrome (EWS) has been investigated in rats. Behavioral EWS symptoms appeared during the first 6 h of ethanol withdrawal. Flumazenil (2.5 and 10 mg/kg i.p.) increased horizontal and vertical locomotor activity significantly and also precipitated abnormal gait and agitation at the beginning of EWS in a dose dependent manner. However, thereafter it reduced the severity of abnormal posture and gait, tail stiffness, agitation and stereotyped behavior in a dose dependent manner. At the 6th hour of EWS, flumazenil (10 mg/kg) reduced total EWS score significantly, but shortened the latency of audiogenic seizures and increased the severity of wet dog shakes. Flumazenil (2.5 and 10 mg/kg) did not elicit behavioral EWS symptoms and audiogenic seizures in non-dependent (control) rats. It did not cause any significant change on locomotor activities in these groups. According to those results, certain actions of flumazenil on the experimental EWS may suggest a potential beneficial effect of this drug in the treatment of EWS in alcoholics, but its enhancing effects on some behavioral EWS symptoms and a potential proconvulsant activity may be a drawback for its use in the treatment of EWS.
    [Abstract] [Full Text] [Related] [New Search]